Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer

Cancer

Volumn 120, Issue 20, 2014, Pages 3131-3141

  Tham, Cheekian ^a   Chew, Minhoe ^b   Soong, Richie ^c,d   Lim, Jitfong ^b   Ang, Meikim ^a   Tang, Choongleong ^b   Zhao, Yi ^b   Ong, Simon Y K ^a   Liu, Yanqun ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Blood markers; Cancer recurrence; Early diagnosis; Epigenetics

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; RETINOIC ACID BINDING PROTEIN; SEPTIN; SEPTIN 9; SOMATOSTATIN; TACHYKININ; TACHYKININ 1; UNCLASSIFIED DRUG; SEPT9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CRABP1 GENE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EARLY DIAGNOSIS; EYA4 GENE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MAL GENE; MALE; NELL1 GENE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN METHYLATION; RECEIVER OPERATING CHARACTERISTIC; SEPT9 GENE; SST GENE; TAC1 GENE; BLOOD; COLORECTAL NEOPLASMS; DNA METHYLATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; SEPTINS; TACHYKININS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908021731     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28802     Document Type: Article

References (19)

1. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872-877.
2. Baca B, Beart RW, Etzioni DA. Surveillance after colorectal cancer resection: a systematic review. Dis Colon Rectum. 2011;54:1036-1048.
3. Rozen M, Chan L, Beart RW, et al. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum. 1998;41:1116-1126.
4. Nicolini A, Ferrari P, Duffy MJ, et al. Intensive risk-adjusted followup with the CEA, TPA, CA 19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrence: effect on survival. Arch Surg. 2010;145:1177-1183.
5. Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis. 1999;14:73-77.
6. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem. 2001;47:624-630.
7. Peach G, Kim C, Zacharakis E, et al. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010;102:1327-1734.
8. Ytting H, Christensen IJ, Thiel S, et al. Pre- and post-operative levels in serum of mannan-binding lectin associated serine protease-2-a prognostic marker in colorectal cancer. Hum Immunol. 2008;69:414-420.
9. Stein U, Burock S, Herrmann P, et al. Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn. 2011;13:189-198.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Colon Cancer. Version 2.2014. http://www.nccn.org/professionals/physicia-gls/f-guidelines.asp#site. Accessed November 16, 2013.
11. Wallner M, Herbst A, Behrens A, et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res. 2006;12:7347-7352.
12. Herbst A, Wallner M, Rahmig K, et al. Methylation of helicase-like transcription factor in serum of patients colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol. 2009;21:565-569.
13. Phillip AB, Stiber P, Nagel D, et al. Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer. 2012;131:2308-2319.
14. Liu Y, Tham CK, Ong SY, et al. Serum methylation levels of TAC1, SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Biomarkers. 2013;8:399-405.
15. Barillari P, Bolognese A, Chirletti P, et al. Role of CEA, TPA, and CA19-9 in the early detection of localized and diffuse recurrent rectal cancer. Dis Colon Rectum. 1992;35:471-476.
16. Uen YH, Lin SR, Wu DC, et al. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg. 2007;246:1040-1046.
17. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood. 1996;88:98-106.
18. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006;131:797-808.
19. Herbst A, Rahmig K, Stieber P, et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol. 2011;106:1110-1118.